apatinib + camrelizumab + nab-paclitaxel

The combination of apatinib, camrelizumab, and nab-paclitaxel is an emerging therapeutic regimen being investigated for various cancer types. This combination integrates targeted therapy (apatinib), immunotherapy (camrelizumab), and chemotherapy (nab-paclitaxel) to potentially enhance anti-tumor effects. Apatinib is an oral tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis[2][6]. Camrelizumab is a humanized IgG4 monoclonal antibody targeting programmed cell death 1 (PD-1), which enhances T-cell immune responses against tumor cells[2][5]. Nab-paclitaxel is a 130 nm particle formulation consisting of paclitaxel and albumin nanoparticles linked by a noncovalent bond, which improves the efficacy and safety profile compared to conventional paclitaxel[2]. ## Clinical Development This combination has shown promising results in several clinical trials: - In pancreatic cancer: A phase II trial demonstrated encouraging antitumor activity and manageable toxicity as first-line therapy for patients with unresectable or metastatic pancreatic cancer. The objective response rate (ORR) was 16.7%, with a disease control rate (DCR) of 91.7%[1][3]. - In lung adenocarcinoma: A multicenter open-label, single-arm phase II trial investigated this combination as first-line treatment for patients with advanced lung adenocarcinoma without EGFR or ALK mutations. Patients received camrelizumab (200 mg intravenously, day one), apatinib (250 mg, q.d., five continuous days per week), and nab-paclitaxel (135 mg/m² intravenously, days one and eight) every three weeks for four to six cycles, followed by maintenance with camrelizumab and apatinib[6]. - In gastric cancer: The combination showed significant benefits in locally advanced gastric cancer (LAGC), with higher pathological response rates compared to chemotherapy alone[2]. - In triple-negative breast cancer (TNBC): The combination demonstrated favorable therapeutic effects and manageable safety profiles in patients with advanced TNBC[5]. ## Safety Profile The most common treatment-related adverse events (TRAEs) include: - Elevated liver enzymes (GGT, ALT, AST, alkaline phosphatase) - Increased blood bilirubin and creatinine - Hand-foot syndrome - Hypoesthesia and malaise Grade ≥3 adverse events occurred in approximately 20-38% of patients across different studies, but most were manageable with dose adjustments or treatment interruptions. No treatment-related deaths were reported in the studies[1][5][7]. The combination appears to have a synergistic effect, with the immunomodulatory properties of apatinib potentially enhancing the efficacy of the PD-1 inhibitor camrelizumab, while nab-paclitaxel provides direct cytotoxic effects against tumor cells.

Brand names

AiRuiKaAiTanAbraxane

Other names

albumin-bound paclitaxel + apatinib + camrelizumabnab-paclitaxel + apatinib + camrelizumab